INTRODUCTION
Glucose-regulated protein 78 (GRP78), also known as BiP/HSPA5, belongs to the HSP70 family. GRP78 is a major endoplasmic reticulum (ER) chaperone protein critical for protein quality control of the ER as well as a master regulator of the unfolded-protein response. 1, 2 Under ER stress, GRP78 is titrated away by the accumulation of malfolded proteins, releasing and activating the unfolded-protein response sensors to restore ER homeostasis. In response to prolonged and severe ER stress, the unfolded-protein response triggers apoptotic pathways leading to cell death. 3 Accumulating evidence indicates that a subfraction of GRP78 localizes at the cell surface under pathological conditions, such as in cancer cells. 2, 4 Cell surface GRP78 acts as a multifunctional receptor to regulate signaling pathways, such as activating the PI3K/AKT signaling for cancer survival and proliferation. 5, 6 Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) are the most common primary liver cancers and are associated with poor prognosis. Currently, a paucity of effective treatments for advanced liver cancers highlights the need to understand liver tumorigenic mechanisms. The tumor suppressor, PTEN (phosphatase and tenson homolog deleted on chromosome 10), which encodes for a non-redundant plasma membrane lipid phosphatase that antagonizes the PI3K signaling pathway, 7 is mutated or deleted in 40-50% of human liver cancers. 8 Loss of PTEN activates the PI3K/AKT pathway, leading to cancer progression in a wide variety of human cancers. Liver-specific PTEN knockout in mice causes fatty liver and liver injury, which activates progenitor cells to become tumor-initiating cells and over time (B12 months) leads to both HCC and CC development. 9, 10 Liver progenitor cells are bi-potential and quiescently reside in the stem cell niche. During chronic or massive liver injury, liver progenitor cells are activated to proliferate and differentiate into hepatocytes and cholangiocytes (bile duct cells). However, deregulated liver progenitors can give rise to liver cancer.
11
GRP78 is commonly upregulated in various tumors because of intrinsic alterations of cancer cell metabolism and hyperproliferation, as well as extrinsic factors in the tumor microenvironment, such as glucose deprivation and hypoxia leading to ER stress. 4, 12 Increased GRP78 is generally associated with greater risk for cancer recurrence and poorer patient outcome. In cancer cell lines and mouse models, GRP78 has been shown to promote tumor survival, progression and resistance to therapy.
For instance, GRP78 deficiency in the mouse prostate epithelium potently suppresses prostate tumorigenesis and AKT activation mediated by the loss of PTEN.
14 Similarly, GRP78 haploinsufficiency blocks Pten-null-mediated leukemia and AKT signaling. 15 In view of these studies, GRP78 might be required for PTEN-loss-driven tumorigenesis. However, several recent studies suggest that in metabolic organs, the effect of GRP78 deletion is complex with both primary and compensatory consequences resulting from partial loss of GRP78. For example, Grp78 heterozygosity protects against high-fat-diet-induced obesity, type 2 diabetes and pancreatitis in the exocrine pancreas through compensatory mechanisms, whereby ER chaperones and other protective ER stress pathways are upregulated. 16, 17 In the case of adipose tissues, GRP78 is required for adipogenesis and glucose homeostasis. 18 In the liver, breeding of Grp78 floxed/floxed mice 14, 19 with the AlbuminCre transgenic mice generated offspring (Alb-Cre; Grp78 f/f ) with incomplete deletion of GRP78. 20 Primary hepatocytes isolated from these mice retained 30% wild-type (WT) level of GRP78. These mice exhibited impaired insulin signaling and exacerbated liver injury resulting from alcohol and high-fat diet and were sensitized to a variety of acute and chronic hepatic disorders, 20 consistent with a protective role of GRP78 in tissues in general.
Taken together, the effects of GRP78 deletion could be tissuespecific and complex. Moreover, the role of GRP78 on PTEN-lossdriven liver cancer development is yet to be determined. Thus, for the present study, we took advantage of the viability of mice with partial hepatic GRP78 deficiency to create a liver-specific biallelic (Pten f/f Grp78 f/f ) deletion mouse model mediated by Alb-Cre, referred to below as cP f/f 78 f/f . Previous reports demonstrated that Alb-Cre is activated at embryonic day 9.5 in fetal hepatoblasts, which are the common progenitors of hepatocytes and bile duct cells. However, postnatally, Alb-Cre activity is maintained in hepatocytes and liver progenitor cells but not in adult bile duct cells. 21, 22 Here, we characterized the phenotypes of cP f/f 78 f/f mice. Our studies revealed that in the context of PTEN deletion, concomitant GRP78 reduction in hepatocytes led to increased hepatomegaly, steatosis, liver injury and progenitor cell proliferation. GRP78 expression in bile duct cells was intact in these mice and bile duct proliferation was readily observed. At 6 months, we detected selective JNK activation, b-catenin downregulation, along with PDGFRa upregulation in cP f/f 78 f/f livers. At 8-9 months, HCC and CC were clearly identified in cP f/f 78 f/f livers, associating with strong GRP78 re-expression. In contrast and despite the development of fatty liver and inflammation, there was no malignancy detected in livers of Alb-Cre; Grp78 f/f (c78 f/f ) mice even at 12-14 months. Overall, these results reveal a novel role of GRP78 in regulating PTEN-loss-mediated liver injury and cancer progression.
RESULTS
Creation of the mouse model with biallelic deletion of GRP78 and PTEN in the liver The breeding scheme for the generation of the following five groups of mouse cohorts is shown in Supplementary Figure S1 In this set of breeding, a different strain of Alb-Cre mice was used from a previous study. 20 This allowed us to test whether the residual GRP78 observed in c78 f/f livers was because of variability of the Cre activity among different transgenic mouse strains.
PCR performed with genomic DNA extracted from the livers of the mouse cohorts validated that the various alleles were excised accordingly. We detected a Pten knockout band in cP f/f mice, a Grp78 knockout band in c78 f/f mice and both Pten and Grp78 knockout bands in cP f/f 78 f/ þ and cP f/f 78 f/f mice but not in WT mice (Figure 1a) . Western blot analysis of liver lysates isolated from 6-month-old mice showed that PTEN knockout was efficient in
and cP f/f 78 f/f mice (around 95% reduction compared with the WT) ( Figure 1b) . As observed previously, 20 GRP78 level only decreased gradually. At 3 months, we detected about 50% reduction in GRP78 in cP f/f 78 f/f and c78 f/f livers and about 70% reduction by 6 months, compared with the WT (Supplementary Figure S2) . cP f/f 78 f/ þ livers showed intermediate GRP78 level (Figure 1b) . In all the mouse cohorts, no compensatory upregulation of the ER chaperone GRP94 was observed. Morphologically, the size of livers with PTEN deficiency increased significantly over WT and c78 f/f livers (Figures 1c and d) . This is likely due in part to enhanced insulin signaling in PTEN-null livers, resulting in redistribution of body fat to the liver as previously reported. 9 Indeed, fat redistribution was also observed in our mouse cohorts, with cP f/f 78 f/f mice exhibiting even lower body (gonadal) fat than cP f/f mice (Supplementary Figures S3a and b) . Livers of cP f/f 78 f/f mice exhibited multiple nodules on the surface as early at 6-7 months, whereas cP f/f and cP f/f 78 f/ þ mice started from 8-9 months and c78 f/f mice from 12-14 months (Figure 1c ). At 6-7 months, the weight of cP f/f 78 f/f livers normalized over body weight, increased fivefold compared with the WT livers and 2.5-fold compared with PTEN-null livers ( Figure 1d ). We observed that cP f/f 78 f/f mice were not viable beyond 9 months. In contrast, the normalized liver weight of c78 f/f mice remained similar to the WT, and these mice were fully viable. Therefore, hepatic GRP78 reduction accelerated PTEN-null-driven hepatomegaly and abnormal nodule growth. ). Recent evidence suggests that the transcription factor XBP-1 is a regulator of hepatic lipogenesis. 23 In the present study, we observed mild Xbp-1 mRNA splicing in c78 f/f livers, which was consistent with previous data. 20 However, Xbp-1 splicing was minimal in cP f/f 78 f/f livers (Supplementary Figure S4a) . ATF4 has also been implicated in lipogenic gene expression; 24 however, we did not detect increased ATF4 protein level in cP f/f 78 f/f livers (Supplementary Figure S4b) .
We measured liver injury by examining plasma alanine aminotransferase (ALT). cP f/f 78 f/f mice displayed 1.7-and 2.3-fold increase in ALT level compared with cP f/f mice at 3 and 6 months, respectively, whereas the ALT level remained at the WT level for livers exhibited a fourfold increase in apoptosis compared with other genotypes (Figure 2e) . Nonetheless, the percentage of apoptosis only reached 2% in cP f/f 78 f/f livers; thus, overall apoptosis in all genotypes was mild at 3 months. Furthermore, none of the genotypes analyzed showed an increase in hepatic expression of the transcription factor CHOP, 3 which is often used as an indicator of ER-stress-induced apoptosis (Supplementary Figure S4c) . This result was consistent with the recent observation that PTEN deletion inhibits thapsigargin-induced CHOP induction in hepatocytes isolated from these mice. 25 GRP78 regulates PTEN-loss-driven liver cancer W-T Chen et al cP f/f 78 f/f livers showed increased proliferation, progenitor cell expansion and GRP78 re-expression in bile duct cells Liver injury generally elicits regeneration through proliferation. 11 To ascertain liver proliferation, we examined Ki67 expression in mouse livers. We observed substantial increase in Ki67-positive cells in cP f/f 78 f/f livers, compared with cP f/f and c78 f/f mice at both 3 and 6 months, whereas Ki67-positive cells were absent in WT livers (Figure 3a) . Additionally, some Ki67-positive cells with liver progenitor cell morphology were detected around bile ducts in cP f/f 78 f/f livers ( Figure 3a) . Liver progenitor markers EpCAM, CK19 and AFP were also upregulated in cP f/f 78 f/f livers compared with WT, cP f/f and c78 f/f livers, which further suggested proliferation ( Figure 3b) .
As demonstrated using western blot analysis, there was residual GRP78 in cP f/f 78 f/f livers. Thus, to gain insight into the distribution pattern of GRP78 in cP f/f 78 f/f mice, we performed immunohistochemical staining of the liver sections. Consistent with our western blot results (Figure 1b and Supplementary Figure S2a) , GRP78 expression progressively decreased between 3 and 6 months of age. Strikingly, the cells of the expanded bile ducts in cP f/f 78 f/f livers showed robust GRP78 staining at both 3 and 6 months ( Figure 3c ). This suggests that some hepatoblasts with incomplete Cre-mediated recombination differentiated into bile ducts, where Alb-Cre was inactive. Moreover, some GRP78-positive cells around bile ducts resembled liver progenitors morphologically (Figure 3c ).
Perturbation of selective signaling pathways in cP f/f 78 f/f livers GRP78 deficiency has been demonstrated to suppress PI3K/AKT signaling. 14, 15 As expected, p-AKT(S473) was highly activated in cP f/f mice, consistent with the established role of PTEN as a negative regulator of PI3K/AKT (Figure 4a ). At 6 months, both p-AKT(S473) and total AKT were dramatically reduced in cP f/f 78 f/f livers, and cP f/f 78 f/ þ livers were also partially affected (Figure 4a ).
Owing to the reduction in total AKT, the functional reduction in p-AKT was not statistically captured through the ratio of p-AKT/ AKT (Figure 4a ). We also detected similar decrease in both p-S6K and S6K, downstream of the AKT pathway, in cP f/f 78 f/f livers (Supplementary Figure S5) . In the case of ERK, similar levels of p-ERK1 and total ERK1 were observed in all the genotypes, whereas the levels of p-ERK2 and total ERK2 decreased in cP In following liver morphology of the mouse cohorts, at the time of killing, all cP f/f 78 f/f mice developed visible tumor-like nodules by 6 months, whereas for cP f/f 78 f/ þ mice, 50% exhibited nodules by 9 months and 100% by 13 months, and for cP f/f mice, liver nodules were not apparent until 12 months (Figure 5a ). c78 f/f livers displayed very few and small nodules at 12-14 months, (Figure 1c ) and hematoxylin and eosin staining showed fatty liver accompanied by inflammation with no sign of malignancy (data not shown). Whereas cP f/f 78 f/f livers showed extensive bile duct proliferation at 6 months (Figure 3c ), hematoxylin and eosin staining revealed no malignancy (data not shown); however, both HCC and CC were evident starting from 8-9 months (Figure 5b ). Intense GRP78 staining was detected in HCC and CC areas in cP f/f 78 f/f livers and GRP78 level in adjacent normal areas was comparable to the WT level (Figure 5b ). We further observed that (Figure 5c ). Taken together, these results suggest that cP f/f 78 f/f mice had accelerated HCC and CC development. Furthermore, HCC and CC areas in the liver were associated with the repopulation with GRP78-positive cells, which may confer selective advantage for the cancer cells.
DISCUSSION
Mutation or deletion of PTEN is commonly observed in liver cancer and GRP78 is required for tumorigenesis in a variety of cancers. 13 In studying the role of GRP78 in liver cancer development using the loss of PTEN as a model system, we made several unexpected discoveries that expand our understanding on how GRP78 regulates tumorigenesis in a metabolic organ. In case of the liver, injury leads to hepatocyte death that in turn activates proliferation of residual hepatocytes and/or liver progenitor cells, which may eventually promote liver cancer. 10, 11 We noted that unlike other tissue-specific knockout models where GRP78 can be nearly completely eliminated, 14, 28, 29 the c78 f/f and cP f/f 78 f/f livers maintained about 30% of WT level of GRP78. This is consistent with a previous study using a different Alb-Cre transgenic mouse strain. 20 Interestingly, both residual white and brown adipose tissues maintain 40% GRP78 expression in adipose Grp78 knockout mice. 18 This suggests that GRP78 may be indispensable for survival in liver and adipose tissues. Whereas male c78 f/f mice maintained in these studies for 14 months showed no malignancy, GRP78 reduction combined with the loss of PTEN led to onset of HCC and CC at 8-9 months. On the basis of our findings, we propose the following model, which is summarized in Figure 5d . In a normal liver, GRP78 is constitutively expressed and maintains liver homeostasis. However, in cP f/f 78 f/f livers, there is loss of PTEN and gradual depletion of GRP78 following Alb-Cre-mediated recombination at 3 months. The loss of GRP78 protection at this stage exacerbates fat accumulation caused by PTEN deficiency. Fatty liver leads to liver injury, which activates bile duct and liver progenitor cell proliferation. At 6 months, JNK activation, coupled with b-catenin loss and PDGFRa upregulation could also contribute to liver injury. 30, 31 At the same time, GRP78 cannot be ablated completely in hepatocytes. Bile duct and progenitor cells that escape Cre exhibit growth advantage and repopulate the liver with GRP78-positive cells. At 
8-9 months, HCC and CC growth is evident in cP
f/f 78 f/f livers, correlating with strong GRP78 expression, and GRP78 level in adjacent normal areas is comparable to the WT level. Whereas the molecular mechanisms leading to these events await future investigations, our results raise several interesting questions.
First, why does GRP78 reduction combined with PTEN deletion in the liver accelerate liver tumorigenesis, whereas GRP78 knockout in other tissues usually inhibits tumor formation? Liver cancer is unique in that cancer arises as a result of injury and regeneration. In the context of PTEN loss, we observed that GRP78 reduction fueled liver steatosis, apparently via a mechanism independent of XBP-1, which led to injury that induced progenitor cell proliferation. If GRP78 expression is eliminated in the tumor cells, tumor development may be arrested as seen in the other cancer models. However, in the case of cP f/f 78 f/f livers, GRP78-positive bile duct and progenitor cells that escaped Alb-Cre repopulated the liver; thus, the developed liver tumors were not handicapped by the lack of GRP78. Consistent with this explanation are the findings that b-catenin-positive cells repopulate b-catenin-null livers because of a progressive loss of Alb-Cre expression, 32 and GRP78-positive cells rapidly repopulate the intestinal epithelium upon genetic knockout in AhCre1-Grp78 f/f mice. 33 With regard to the origin of the HCC and CC in cP f/f 78 f/f livers, HCC and CC could be derived from liver progenitor cells. 11 Our immunohistochemistry data indicated strong GRP78 expression in HCC and CC tissues and that some cells around proliferating bile ducts exhibited liver progenitor cell morphology and also expressed GRP78. These observations suggest the possibility that liver progenitor cell is the origin of malignancies. Interestingly, transdifferentiation of hepatocytes to bile duct epithelial cells has been demonstrated. 34 Conversely, some biliary epithelial cells appear capable of differentiating to hepatocytes. 35 Thus, future studies will be required to address whether the GRP78-positive bile duct cells give rise to GRP78-positive liver cancers.
GRP78 overexpression has been reported in various tumors, including HCC. 36, 37 As the major chaperone with potent antiapoptotic properties and a signaling regulator, GRP78 protects tumor cells from ER stress and host cell defense, thereby promoting tumor growth. This is consistent with our observation that GRP78 was upregulated in cP f/f liver tumors (Supplementary Figure S6) . GRP78 has been reported to protect liver cancer cells from ER-stress-induced apoptosis and promote their invasion in a metastasis model. 37, 38 Thus, robust GRP78 expression may indeed be required for liver cancer progression. As several therapeutics against GRP78 are in development, 13 it will be interesting to treat liver cancer with these agents to see whether they can block the re-expression of GRP78 and suppress liver cancer progression while maintaining essential liver functions. In treatment of other cancers with anti-GRP78 agents, as the adult liver can function normally with partial GRP78 level, whereas cancer requires high level of GRP78, the damage to the normal liver may be limited. As reported recently, antibodies against cell surface GRP78 were well tolerated in pharmacokinetic/toxicology studies in mice, monkeys and patients. 39, 40 The JNK signaling pathway has been linked to the growth of carcinogen-induced HCC, and about 50-60% of human HCC show strong activation of JNK1. 41 The function of sustained JNK activation in hepatocyte death and subsequent inflammation and carcinogenesis is recapitulated in various genetic mouse models developing HCC. 30 Our results revealed that p-JNK was moderately elevated in cP f/f 78 f/f livers at 6 months, accompanied by increased inflammation (data not shown) prior to HCC and CC formation, suggesting that JNK might partially contribute to accelerated liver tumorigenesis. Whereas this requires validation, the extent of apoptosis remained low (below 2%) in cP f/f 78 f/f livers at 6 months (data not shown); thus, moderate activation of JNK in these livers did not majorly affect apoptosis linked to sustained activation of JNK.
b-catenin signaling, the central effector of the canonical Wnt signaling pathway and a recognized oncogene, is also implicated in HCC. However, overexpressing b-catenin in transgenic mouse models has not exhibited spontaneous HCC. 31 Paradoxically, hepatic b-catenin loss impairs the ability of the liver to counteract DEN-induced oxidative stress and enhances HCC through PDGFRa/PI3K/AKT(Thr308 phosphorylation) signaling. 26 Furthermore, hepatic b-catenin deletion increases fatty liver and steatohepatitis under diet-induced metabolic stress. 42 These results suggest that b-catenin loss can sensitize livers to injury and eventually tumorigenesis, which mimics the predominant scenario of human HCC where tumors often occur in steatohepatitis or cirrhosis background. 31 cP f/f 78 f/f livers exhibited enhanced injury compared with cP f/f livers, and we observed b-catenin downregulation along with PDGFRa upregulation and significantly increased p-AKT(Thr308) (data not shown) in the liver at 6 months. Oxidative stress and overexpression of PDGF have been reported in PTEN-null livers. 10 In combination, these factors might promote PDGFRa activation. Therefore, it is tempting to speculate that increased PDGFRa may be one of the mechanisms in our model to accelerate liver tumors, and hepatic b-catenin loss might also sensitize the liver to the injury induced by PTEN and GRP78 double knockout, further promoting tumorigenesis. Liver fat accumulation, injury and tumorigenesis can be also promoted by the loss of autophagy, which can be monitored by increase in P62. 43 Interestingly, we observed a trend of increased P62 level in cP f/f 78 f/f livers, suggesting the perturbation of autophagy (Supplementary Figure S7) . Future studies are required to address 
MATERIALS AND METHODS Mice

Grp78
f/f mice on a mixed C57BL/6;129/Sv background 14, 19 and Pten
mice on a C57BL/6;6 Â DBA2;129 background were previously described. ) and Alb-Cre; Pten Figure S1) . Littermates that were negative for the Cre transgene were used as WT controls. Male mice were used in all experiments. Genotyping was performed with PCR using genomic DNA extracted from mouse tails and liver biopsies as previously described. 14 Blood samples were collected through retro-orbital bleeding prior to tissue collection. All protocols for animal use were reviewed and approved by the USC Institutional Animal Care and Use Committee.
Histology
Mice were euthanized and their livers were removed and rinsed in phosphate-buffered saline. Samples collected from the livers were immediately frozen for RNA and protein extraction, fixed in 10% zinc formalin or frozen in OCT compound (Tissue-Tek Sakura, Torrance, CA, USA). Formalin-fixed tissue samples were embedded in paraffin, sectioned at 4 mm and stained with hematoxylin and eosin for morphology analysis. Frozen tissue samples were sectioned at 10 mm for Oil Red O staining.
Immunohistochemistry staining
The staining procedures of paraffin sections were performed as described.
14 Polyclonal rabbit anti-GRP78 (H-129, 1:100, Santa Cruz Biotechnology, Dallas, TX, USA) antibody was used to determine GRP78 levels in the liver. Cell proliferation was evaluated by Ki67 staining (Ab-4, 1:200, Thermo Scientific, Fremont, CA, USA).
Oil Red O staining
Frozen liver sections were briefly fixed in cold 10% formalin. Slides were stained in Oil Red O solution (3 mg/ml) and hematoxylin for counterstain.
Plasma ALT quantitation
Plasma ALT was determined using ALT Reagent (Raichem, San Diego, CA, USA). 
Western blot analyses
Western blot analyses were performed as described. 14 Liver samples were homogenized in RIPA buffer with added protease and phosphatase inhibitor cocktail (Pierce, Rockford, IL, USA) and 25 mg cell lysate was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The immunoblot membranes were incubated with primary antibodies at 4 1C overnight and the protein signals were detected with ECL reagent or SuperSignal West Femto stable peroxide buffer (Pierce) after reacting with horse radish peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology). The primary antibodies used are as follows: Monoclonal mouse anti-GRP78 ( Real-time quantitative PCR RNA was extracted from mouse livers, and reverse transcription and real-time PCR were performed as previously described. 44 Primers used for AFP, EpCAM, CK19 and 18S RNA have been described. 10, 45 The following primers were used for lipogenic genes: SREBP-1c, 
Statistical analysis
Statistical significance was assayed by two-tailed Student's t-test, and the error bars reflect s.e.
